Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMP4 | P12644 | 4/20 | 1.00 |
| ▸ | BMPR1B | O00238 | 16/20 | 0.80 |
| ▸ | ACVRL1 | P37023 | 16/20 | 0.80 |
| ▸ | ACVR1 | Q04771 | 16/20 | 0.80 |
| ▸ | BMPR1A | P36894 | 15/20 | 0.80 |
| ▸ | ACVR1B | P36896 | 10/20 | 0.80 |
| ▸ | KDR | P35968 | 2/20 | 0.76 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.76 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.76 |
| ▸ | BMPR2 | Q13873 | 2/20 | 0.76 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.76 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.76 |
| ▸ | ACVR2A | P27037 | 1/20 | 0.76 |
| ▸ | ACVR2B | Q13705 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16111479 | 0.89 | BMPR1B (1.00) | BMP4BMPR1BACVRL1ACVR1BMPR1A | |
| SCHEMBL12779921 | 0.89 | BMPR1B (0.80) | BMP4BMPR1BACVRL1ACVR1BMPR1A | |
| SCHEMBL16112592 | 0.89 | BMPR1B (1.00) | BMP4BMPR1BACVRL1ACVR1BMPR1A | |
| SCHEMBL29353046 | 0.87 | ACVR1 (1.00) | BMP4BMPR1BACVRL1ACVR1BMPR1A | |
| SCHEMBL456393 | 0.87 | ACVR1 (1.00) | BMP4BMPR1BACVRL1ACVR1BMPR1A | |
| SCHEMBL26867530 | 0.86 | BMPR1B (0.84) | BMP4BMPR1BACVRL1ACVR1BMPR1A | |
| SCHEMBL16112348 | 0.86 | ACVR1 (1.00) | BMP4BMPR1BACVRL1ACVR1BMPR1A | |
| SCHEMBL16112027 | 0.86 | BMPR1B (1.00) | BMP4BMPR1BACVRL1ACVR1BMPR1A | |
| Hypochlorous Acid SCHEMBL26968209 | 0.86 | ACVR1B (0.94) | BMP4BMPR1BACVRL1ACVR1BMPR1A | |
| Hydrochloric Acid SCHEMBL2059683 | 0.86 | ACVR1 (0.98) | BMP4BMPR1BACVRL1ACVR1BMPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372390-A1 | METHODS OF TREATING LYMPHOPENIA | KEROS THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20160263117-A1 | COMPOSITIONS AND METHODS FOR CARDIOVASCULAR DISEASE | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2016-09-15 | — | — | US | disclosed |
| US-20160263117-A1 | COMPOSITIONS AND METHODS FOR CARDIOVASCULAR DISEASE | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2016-09-15 | — | — | US | disclosed |
| EP-2265603-B1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | GEN HOSPITAL CORP (US) | 2014-05-07 | — | — | EP | disclosed |
| WO-2012100229-A2 | COMPOSITIONS AND METHODS FOR CARDIOVASCULAR DISEASE | THE GENERAL HOSPITAL CORPORATION (US) | 2012-07-26 | — | — | WO | disclosed |
| WO-2009114180-A1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | THE GENERAL HOSPITAL CORPORATION (US) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160263117-A1 | COMPOSITIONS AND METHODS FOR CARDIOVASCULAR DISEASE | APOB, BMP1, LDLR | BMP4 8/4885BMPR1B 5/4885ACVRL1 24/4885 |
| US-20230372390-A1 | METHODS OF TREATING LYMPHOPENIA | HAMP, BMPR2, BMP2 | BMP4 17/4885BMPR1B 5/4885ACVRL1 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.